Format

Send to

Choose Destination
Eur Heart J. 2013 Feb;34(6):432-42. doi: 10.1093/eurheartj/ehs235. Epub 2012 Aug 8.

Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar).

Author information

1
Department of Cardiology and Endocrinology, Frederiksberg University Hospital, DK-2000 Frderiksberg, Denmark. m.schou@dadlnet.dk

Abstract

BACKGROUND:

Outpatient follow-up in specialized heart failure clinics (HFCs) is recommended by current guidelines and implemented in most European countries, but the optimal duration of HFC programmes has not been established. Nor is it known whether all or only high-risk patients, e.g. identified by NT-proBNP, might benefit from an extended HFC follow-up.

METHODS AND RESULTS:

In a multi-centre setting, we randomly assigned 921 clinically stable systolic heart failure (HF) outpatients on optimal medical therapy to undergo either an extended follow-up in the HFC (n = 461) or referral back to their general practitioner (GP) (n = 460). The primary composite endpoint was death or a cardiovascular admission. Secondary endpoints included mortality, an HF admission, quality of life, number of days admitted, and number of admissions. The median age of the patients was 69 years; 23% were females; the median left ventricular ejection fraction was 0.30; and the median NT-proBNP was 801 pg/mL; 89% were in NYHA class I-II. The median follow-up was 2.5 years. Time-to-event did not differ between groups (HFC vs. GP) (HR: 1.17, 95% CI: 0.95-1.45, P = 0.149). The two groups did not differ with respect to any of the secondary endpoints at the follow-up (P> 0.05 for all). In high-risk patients identified by NT-proBNP ≥1000 pg/mL, no benefit from HFC follow-up was found (P = 0.721).

CONCLUSION:

Irrespective of the level of NT-proBNP stable HF patients on optimal medical therapy do not benefit from long-term follow-up in a specialized HFC in a publicly funded universal access healthcare system. Heart failure patients on optimal medical therapy with mild or moderate symptoms are safely managed by their personal GP.

TRIAL REGISTRATION:

www.Centerwatch.com: 173491 (NorthStar).

PMID:
22875412
DOI:
10.1093/eurheartj/ehs235
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center